{
 "name": "華安",
 "slug": "tw-6657",
 "aliases": [
  "華安醫學股份有限公司",
  "ENERGENESIS",
  "6657"
 ],
 "ticker": "6657",
 "industry": "生技醫療業",
 "website": "http://www.energenesis-biomedical.com",
 "summary": "華安（6657）是上市的生技醫療類股公司，2012 年成立，2023 年上市。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "華安醫學股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "英文簡稱",
   "value": "ENERGENESIS",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "掛牌市場",
   "value": "臺灣證券交易所上市",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "上市日期",
   "value": "2023-06-12",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "成立日期",
   "value": "2012-08-28",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "董事長",
   "value": "陳翰民",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "總經理",
   "value": "江銘燦",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "實收資本額",
   "value": 897490000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "勤業眾信聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "公司網址",
   "value": "http://www.energenesis-biomedical.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 434,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap05_L",
   "note": "原檔二手來源不在白名單；回查官方115年09月營收申報，claim/value/unit/as_of與原值一致並保留。出表日期1151017；僅更正source及補note。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": -43.78,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap05_L",
   "note": "原檔二手來源不在白名單；回查官方115年09月營收申報，claim/value/unit/as_of與原值一致並保留。出表日期1151017；僅更正source及補note。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": 4.84,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap05_L",
   "note": "原檔二手來源不在白名單；回查官方115年09月營收申報，claim/value/unit/as_of與原值一致並保留。出表日期1151017；僅更正source及補note。"
  },
  {
   "claim": "管線：ENERGI-F703DFU（ENERGI-F703 GEL）",
   "value": "糖尿病足潰瘍｜III期（登錄收案中；最後更新2025-10-02）｜台灣、美國",
   "unit": "",
   "as_of": "2025-10-02",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05930210",
   "note": "NCT 編號：NCT05930210；as_of 為登錄最後更新公開日。登錄舊預估完成日已過，未有完成證據；不當作2026新催化劑。"
  },
  {
   "claim": "管線：ENERGI-F703EB（外用乳膏）",
   "value": "遺傳性表皮分解性水皰症｜II期（收案中）｜台灣",
   "unit": "",
   "as_of": "2026-10-05",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07858422",
   "note": "NCT 編號：NCT07858422；as_of 為登錄最後更新公開日。"
  },
  {
   "claim": "管線：ENERGI-F703VLU（ENERGI-F703 GEL）",
   "value": "下肢靜脈潰瘍｜II期（登錄狀態UNKNOWN；最後已知為收案中）｜台灣",
   "unit": "",
   "as_of": "2024-02-20",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT04078555",
   "note": "NCT 編號：NCT04078555；as_of 為登錄最後更新公開日。登錄最後更新2024-02-20，現況待補；不視為目前仍收案。"
  },
  {
   "claim": "管線：ENERGI-F701（防止落髮外用液劑）",
   "value": "女性型落髮｜II期試驗已完成（歷史登錄）｜台灣",
   "unit": "",
   "as_of": "2020-11-24",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT03351322",
   "note": "NCT 編號：NCT03351322；as_of 為登錄最後更新公開日。不推定已進入III期或上市。"
  },
  {
   "claim": "管線：ENERGI-F705PD（ENERGI-F705口服錠）",
   "value": "巴金森氏症｜II期（台灣登錄尚未收案）｜台灣",
   "unit": "",
   "as_of": "2026-07-02",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07647614",
   "note": "NCT 編號：NCT07647614；as_of 為登錄最後更新公開日。同產品美國二期IND另於2026-07-27接獲暫停通知，見另筆MOPS；不得把台灣登錄視為美國獲准。"
  },
  {
   "claim": "管線：ENERGI-F705PD（ENERGI-F705口服藥）",
   "value": "巴金森氏症｜美國II期IND申請收到暫停通知，待完整意見後修正回覆｜美國",
   "unit": "",
   "as_of": "2026-07-27",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&year=115&month=all&step=2&seq_no=2&spoke_time=165832&spoke_date=20260727&co_id=6657&TYPEK=sii",
   "note": "發言日期：2026-07-27 16:58:32；主旨：本公司研發中新藥ENERGI-F705PD巴金森氏症口服藥向美國FDA申請人體二期臨床試驗案接獲通知。。"
  },
  {
   "claim": "授權合作：ENERGI-F703DFU",
   "value": "TRPHARM FZ-LLC｜土耳其｜2023-11-10",
   "unit": "",
   "as_of": "2023-11-10",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&year=112&month=all&step=2&seq_no=2&spoke_time=144303&spoke_date=20231110&co_id=6657&TYPEK=sii",
   "note": "發言日期：2023-11-10 14:43:03；主旨：公告本公司與TRPHARM FZ-LLC簽訂專屬授權合約，將ENERGI-F703用於治療糖尿病足潰瘍適應症授予TRPHARM FZ-LLC在土耳其商業化權利及中東、獨立國協及北非市場之優先議約權。。中東、獨立國協及北非僅為優先議約權，不列已授權區域。"
  },
  {
   "claim": "授權合作：ENERGI-F703DFU",
   "value": "Pharma Bavaria Internacional (PBI) Portugal Unipessoal Lda.｜葡萄牙、中東｜2024-10-11",
   "unit": "",
   "as_of": "2024-10-11",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&year=113&month=all&step=2&seq_no=1&spoke_time=154241&spoke_date=20241011&co_id=6657&TYPEK=sii",
   "note": "發言日期：2024-10-11 15:42:41；主旨：公告本公司與德國Pharma Bavaria Internacional集團全資子公司PBI Portugal Unipessoal Lda.簽訂專屬授權合約。。非洲及中美洲須依開發里程另議，未列已生效授權區域。"
  },
  {
   "claim": "授權合作：ENERGI-F703DFU",
   "value": "台灣田邊製藥股份有限公司｜台灣｜2026-08-06",
   "unit": "",
   "as_of": "2026-08-06",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&year=115&month=all&step=2&seq_no=1&spoke_time=153733&spoke_date=20260806&co_id=6657&TYPEK=sii",
   "note": "發言日期：2026-08-06 15:37:33；主旨：公告本公司與田邊製藥台灣子公司台灣田邊製藥股份有限公司簽訂合作開發合約。。共同開發暨技術移轉合作，目的為台灣取證後銷售，並非公告已授予商業化獨家授權。合約期至2028-11-30。"
  },
  {
   "claim": "權利金比率：ENERGI-F703DFU／TRPHARM",
   "value": 25,
   "unit": "%",
   "as_of": "2023-11-10",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&year=112&month=all&step=2&seq_no=2&spoke_time=144303&spoke_date=20231110&co_id=6657&TYPEK=sii",
   "note": "發言日期：2023-11-10 14:43:03；主旨：公告本公司與TRPHARM FZ-LLC簽訂專屬授權合約，將ENERGI-F703用於治療糖尿病足潰瘍適應症授予TRPHARM FZ-LLC在土耳其商業化權利及中東、獨立國協及北非市場之優先議約權。。計算基礎為銷售毛利；非銷售額的25%。"
  },
  {
   "claim": "權利金比率：ENERGI-F703DFU／PBI Portugal",
   "value": 50,
   "unit": "%",
   "as_of": "2024-10-11",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&year=113&month=all&step=2&seq_no=1&spoke_time=154241&spoke_date=20241011&co_id=6657&TYPEK=sii",
   "note": "發言日期：2024-10-11 15:42:41；主旨：公告本公司與德國Pharma Bavaria Internacional集團全資子公司PBI Portugal Unipessoal Lda.簽訂專屬授權合約。。公告原稱分潤金；基礎為銷售毛利扣除行銷費用及銷售運費，非淨銷售額的50%。"
  },
  {
   "claim": "催化劑：ENERGI-F703EB",
   "value": "II期試驗預估主要完成日｜2027-03-15（登錄預估）｜已公告",
   "unit": "",
   "as_of": "2026-10-05",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07858422",
   "note": "NCT 編號：NCT07858422；ESTIMATED 日期是試驗登錄者預估，非主管機關保證或結果公布日期。"
  },
  {
   "claim": "催化劑：ENERGI-F703EB",
   "value": "II期試驗預估全部完成日｜2027-06-15（登錄預估）｜已公告",
   "unit": "",
   "as_of": "2026-10-05",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07858422",
   "note": "NCT 編號：NCT07858422；ESTIMATED 日期是試驗登錄者預估，非主管機關保證或結果公布日期。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6657.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}